Murine Oncostatin M Has Opposing Effects on the Proliferation of OP9 Bone Marrow Stromal Cells and NIH/3T3 Fibroblasts Signaling through the OSMR
暂无分享,去创建一个
R. Oostendorp | C. Miething | J. Duyster | J. Mitschke | Lena Jakob | D. Pfeifer | M. Waterhouse | T. A. Müller | P. Veratti | M. Rassner | H. Kleinfelder | T. Müller
[1] G. Müller-Newen,et al. Oncostatin M regulates hematopoietic stem cell (HSC) niches in the bone marrow to restrict HSC mobilization , 2021, Leukemia.
[2] André F. Rendeiro,et al. STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway , 2020, Oncogene.
[3] A. Zekiy,et al. Oncostatin M: A mysterious cytokine in cancers. , 2020, International immunopharmacology.
[4] F. Tang,et al. Single-Cell Multiomics Sequencing Reveals Prevalent Genomic Alterations in Tumor Stromal Cells of Human Colorectal Cancer. , 2020, Cancer cell.
[5] R. Moriggl,et al. Targeting STAT3 and STAT5 in Cancer , 2020, Cancers.
[6] Hao Wang,et al. Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways , 2020, Experimental physiology.
[7] M. Mohty,et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. , 2020, The New England journal of medicine.
[8] A. J. Thompson,et al. Evidence for an effect of receptor density on ligand occupancy and agonist EC50 , 2019, Scientific Reports.
[9] C. Drake,et al. A Subset of TREM2+ Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair Growth. , 2019, Cell stem cell.
[10] Alireza Hadj Khodabakhshi,et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.
[11] Zhenghui Liu,et al. Endothelial signaling by neutrophil-released oncostatin M enhances P-selectin-dependent inflammation and thrombosis. , 2019, Blood advances.
[12] Judith A. Blake,et al. Mouse Genome Database (MGD) 2019 , 2018, Nucleic Acids Res..
[13] R. Majeti,et al. Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis , 2018, Science Advances.
[14] P. Denormandie,et al. Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications. , 2017, JCI insight.
[15] R. Owens,et al. Oncostatin M drives intestinal inflammation in mice and its abundance predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease , 2017, Nature Medicine.
[16] G. Smyth,et al. Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass* , 2016, The Journal of Biological Chemistry.
[17] S. Rose-John,et al. The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth , 2016, Oncotarget.
[18] L. Hennighausen,et al. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3+-mediated leukemic phenotype , 2016, Leukemia.
[19] R. Oostendorp,et al. Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression , 2016, The Journal of experimental medicine.
[20] W. Lee,et al. Adiponectin Induces Oncostatin M Expression in Osteoblasts through the PI3K/Akt Signaling Pathway , 2015, International journal of molecular sciences.
[21] A. Christiano,et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth , 2015, Science Advances.
[22] D. Smyth,et al. Oncostatin M regulates osteogenic differentiation of murine adipose-derived mesenchymal progenitor cells through a PKCdelta-dependent mechanism , 2015, Cell and Tissue Research.
[23] M. Griesshammer,et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. , 2015, The New England journal of medicine.
[24] J. Prados,et al. Serum Cytokine Profile in Patients With Pancreatic Cancer , 2014, Pancreas.
[25] P. Watson,et al. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer , 2014, Oncogene.
[26] X. Chen,et al. Stat3-coordinated Lin-28–let-7–HMGA2 and miR-200–ZEB1 circuits initiate and maintain oncostatin M-driven epithelial–mesenchymal transition , 2013, Oncogene.
[27] B. Trigatti,et al. Oncostatin M and TLR-4 Ligand Synergize to Induce MCP-1, IL-6, and VEGF in Human Aortic Adventitial Fibroblasts and Smooth Muscle Cells , 2013, Mediators of inflammation.
[28] J. H. Kim,et al. Oncostatin M promotes mesenchymal stem cell-stimulated tumor growth through a paracrine mechanism involving periostin and TGFBI. , 2013, The international journal of biochemistry & cell biology.
[29] Ellen T. Gelfand,et al. The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.
[30] Xin Zhang,et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. , 2012, Cell stem cell.
[31] O. Lee,et al. Oncostatin m modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect. , 2012, Cancer research.
[32] O. Delattre,et al. Oncostatin M is a growth factor for Ewing sarcoma. , 2012, The American journal of pathology.
[33] S. Chevalier,et al. Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M Signaling , 2012, Stem cells.
[34] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[35] Ying Yue,et al. Oncostatin M promotes proliferation of ovarian cancer cells through signal transducer and activator of transcription 3. , 2011, International journal of molecular medicine.
[36] D. Heymann,et al. Direct anti‐cancer effect of oncostatin M on chondrosarcoma , 2011, International journal of cancer.
[37] Jonas Renström,et al. How the niche regulates hematopoietic stem cells. , 2010, Chemico-biological interactions.
[38] T. Martin,et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. , 2010, The Journal of clinical investigation.
[39] L. Hennighausen,et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. , 2009, Blood.
[40] K. Götze,et al. Oncostatin M‐Mediated Regulation of KIT‐Ligand‐Induced Extracellular Signal‐Regulated Kinase Signaling Maintains Hematopoietic Repopulating Activity of Lin−CD34+CD133+ Cord Blood Cells , 2008, Stem cells.
[41] M. Mansukhani,et al. Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha , 2008, Molecular Cancer.
[42] D. Smyth,et al. Oncostatin M-Induced IL-6 Expression in Murine Fibroblasts Requires the Activation of Protein Kinase Cδ1 , 2006, The Journal of Immunology.
[43] Y. Hirabayashi,et al. Oncostatin M Maintains the Hematopoietic Microenvironment and Retains Hematopoietic Progenitors in the Bone Marrow , 2006, International journal of hematology.
[44] J. Pfeilschifter,et al. Oncostatin M expression is functionally connected to neutrophils in the early inflammatory phase of skin repair: implications for normal and diabetes-impaired wounds. , 2006, The Journal of investigative dermatology.
[45] C. Keller-Peck,et al. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. , 2005, Cancer research.
[46] D. Fuchs,et al. Interleukin‐6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen‐activated protein kinase and phosphatidylinositol 3‐kinase , 2005, The Prostate.
[47] M. Katsuki,et al. Targeted disruption of oncostatin M receptor results in altered hematopoiesis. , 2003, Blood.
[48] C. Miething,et al. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. , 2003, Blood.
[49] K. Nilsson,et al. Ser727/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0/G1 arrest of U-937 cells. , 2003, Blood.
[50] R. DePinho,et al. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. , 2002, Immunity.
[51] L. Naeger,et al. Th1 cells regulate hematopoietic progenitor cell homeostasis by production of oncostatin M. , 2002, Immunity.
[52] K. Chida,et al. Oncostatin M production by human dendritic cells in response to bacterial products. , 2002, Cytokine.
[53] M. Obinata,et al. Oncostatin M regulates mesenchymal cell differentiation and enhances hematopoietic supportive activity of bone marrow stromal cell lines , 2001, In Vitro Cellular & Developmental Biology - Animal.
[54] C. Nordborg,et al. Expression of the IL-6 family cytokines in human brain tumors. , 2001, International journal of oncology.
[55] Jingwen Liu,et al. Oncostatin M–induced growth inhibition and morphological changes of MDA‐MB231 breast cancer cells are abolished by blocking the MEK/ERK signaling pathway , 2001, Breast Cancer Research and Treatment.
[56] H. Halfter,et al. Complete inhibition of in vivo glioma growth by oncostatin M , 2001, Journal of neurochemistry.
[57] M. Dehoux,et al. Oncostatin M Production by Blood and Alveolar Neutrophils during Acute Lung Injury , 2001, Laboratory Investigation.
[58] P. Heinrich,et al. Non-redundant Signal Transduction of Interleukin-6-type Cytokines , 2000, The Journal of Biological Chemistry.
[59] M. Loh,et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. , 2000, Molecular cell.
[60] A. Miyajima,et al. Role of Oncostatin M in hematopoiesis and liver development. , 2000, Cytokine & growth factor reviews.
[61] J. Tavernier,et al. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. , 1999, Journal of immunology.
[62] B. Bonavida,et al. Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. , 1999, Anticancer research.
[63] A. Boutten,et al. Oncostatin M production and regulation by human polymorphonuclear neutrophils. , 1999, Blood.
[64] M. Ichihara,et al. Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice. , 1997, Blood.
[65] C. Guillet,et al. Signaling of Type II Oncostatin M Receptor* , 1997, The Journal of Biological Chemistry.
[66] L. Hennighausen,et al. Stat5a is mandatory for adult mammary gland development and lactogenesis. , 1997, Genes & development.
[67] K. Pulkki,et al. Serum oncostatin M in multiple myeloma: association with prognostic factors , 1997, British journal of haematology.
[68] D. Friend,et al. Dual Oncostatin M (OSM) Receptors , 1996, The Journal of Biological Chemistry.
[69] J. Darnell,et al. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[70] Xin-Yuan Fu,et al. Cell Growth Arrest and Induction of Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Mediated by STAT1 , 1996, Science.
[71] H. Haugen,et al. Developmental abnormalities in mice transgenic for bovine oncostatin M , 1995, Molecular and cellular biology.
[72] Comeau,et al. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. , 1992, Science.
[73] J. Liu,et al. Regulation of IL-6 expression by oncostatin M. , 1991, Journal of immunology.
[74] T. Hirano,et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.
[75] H. Marquardt,et al. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. , 1987, Journal of immunology.
[76] G. Todaro,et al. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[77] A. Zorluoğlu,et al. Oncostatin-M as a novel biomarker in colon cancer patients and its association with clinicopathologic variables. , 2014, European review for medical and pharmacological sciences.
[78] J. Marrero,et al. Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. , 2012, Cancer biomarkers : section A of Disease markers.
[79] S. Jo,et al. Oncostatin M induces growth arrest of skeletal muscle cells in G1 phase by regulating cyclin D1 protein level. , 2008, Cellular signalling.
[80] P. Heinrich,et al. Oncostatin M-induced activation of stress-activated MAP kinases depends on tyrosine 861 in the OSM receptor and requires Jak1 but not Src kinases. , 2006, Cellular signalling.
[81] M. Błasińska-Morawiec,et al. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission. , 1999, Mediators of inflammation.
[82] J. Aster,et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. , 1998, Blood.
[83] T. Hirano,et al. Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily , 1994, Stem cells.
[84] P. Linsley,et al. Regulation of cell growth by recombinant oncostatin M. , 1990, Growth factors.